Sarcoma Clinical Trials

A listing of Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 89 clinical trials
None
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of …

dyspnea at rest
platelet transfusion
neutrophil count
chemotherapeutic agents
hematopoietic growth factors
  • 261 views
  • 29 Nov, 2021
  • 82 locations
None
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond …

packed red blood cells
platelet transfusion
neutrophil count
chemotherapeutic agents
hematopoietic growth factors
  • 199 views
  • 29 Nov, 2021
  • 76 locations
None
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets …

  • 0 views
  • 15 Nov, 2021
  • 5 locations
None
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

interleukin 2
measurable disease
mammogram
  • 0 views
  • 28 Nov, 2021
  • 5 locations
None
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)

, skin cancer, sarcoma, liposarcoma, and liver cancer. The participants get a combination of 3 medicines called BI 907828, BI 754091, and BI 754111. BI 907828 is a so-called MDM2 inhibitor that is being

carcinoma
targeted therapy
metastasis
solid neoplasm
TP53
  • 6 views
  • 24 Nov, 2021
  • 6 locations
None
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Immunotherapy with monoclonal antibodies, such as pembrolizumab, …

targeted therapy
carcinoma
human immunodeficiency virus
direct bilirubin
mk-3475
  • 142 views
  • 28 Nov, 2021
  • 5 locations
None
Individualized Assessment and Treatment for TMD

Temporomandibular/orofacial pain disorders (TMD) are a group of painful conditions with multiple determinants.This proposal has two main goals: 1) to test a highly individualized, adaptive treatment for TMD that has potential to be more effective than other psychosocial treatments; and 2) to discover the mechanisms by which psychosocial treatments work …

headache
chronic pain
  • 0 views
  • 25 Nov, 2021
  • 1 location
None
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability …

prophylactic cranial irradiation
antiretroviral therapy
leptomeningeal disease
neutrophil count
monoclonal antibodies
  • 0 views
  • 29 Nov, 2021
  • 434 locations
None
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Background NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems. The only treatment is surgery. Researchers want to see if a drug called abemaciclib can help. Objective To find a safe, tolerable dose of abemaciclib for treating …

dysplasia
measurable disease
serum pregnancy test
nf1 mutation
ejection fraction
  • 0 views
  • 28 Nov, 2021
  • 1 location
None
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

carcinoma
metastasis
cancer
sirolimus
solid tumour
  • 0 views
  • 20 Nov, 2021
  • 7 locations